WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125680


Description: NOTA-octreotide is a ligand for making [18F]AlF-NOTA-octreotide, which is a PET/CT imaging agent for somatostatin receptor imaging in neuroendocrine tumor patients

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 125680
Name: NOTA-octreotide
Chemical Formula: C61H85N13O15S2
Exact Mass: 1,303.57
Molecular Weight: 1,304.550
Elemental Analysis: C, 56.16; H, 6.57; N, 13.96; O, 18.40; S, 4.92

Price and Availability

Size Price Availability Quantity
5mg USD 1650 2 Weeks
10mg USD 2950 2 Weeks
100mg USD 6950 2 Weeks
Bulk inquiry

Synonym: NOTA-octreotide; NOTA octreotide; NOTAoctreotide

IUPAC/Chemical Name: 2,2'-(7-(2-(((R)-1-(((4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-10-(4-aminobutyl)-16-benzyl-4-(((2S,3R)-1,3-dihydroxybutan-2-yl)carbamoyl)-7-((S)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-1,4,7-triazonane-1,4-diyl)diacetic acid


InChi Code: InChI=1S/C61H85N13O15S2/c1-37(76)48(34-75)68-60(88)50-36-91-90-35-49(69-56(84)45(27-39-13-5-3-6-14-39)64-51(78)31-72-21-23-73(32-52(79)80)25-26-74(24-22-72)33-53(81)82)59(87)66-46(28-40-15-7-4-8-16-40)57(85)67-47(29-41-30-63-43-18-10-9-17-42(41)43)58(86)65-44(19-11-12-20-62)55(83)71-54(38(2)77)61(89)70-50/h3-10,13-18,30,37-38,44-50,54,63,75-77H,11-12,19-29,31-36,62H2,1-2H3,(H,64,78)(H,65,86)(H,66,87)(H,67,85)(H,68,88)(H,69,84)(H,70,89)(H,71,83)(H,79,80)(H,81,82)/t37-,38+,44+,45-,46+,47-,48+,49+,50+,54+/m1/s1

SMILES Code: O=C(N[C@H](CC1=CC=CC=C1)C(N[C@@H]2C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](C(N[C@@H](CCCCN)C(N[C@@H]([C@H](C)O)C(N[C@@H](CSSC2)C(N[C@H]([C@H](O)C)CO)=O)=O)=O)=O)CC4=CNC5=C4C=CC=C5)=O)=O)=O)CN6CCN(CC(O)=O)CCN(CC(O)=O)CC6

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,304.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, Deroose
CM, Cleeren F. Automated GMP compliant production of [18F]AlF-NOTA-
octreotide. EJNMMI Radiopharm Chem. 2020 Jan 29;5(1):4. doi:
10.1186/s41181-019-0084-1. PMID: 31997090; PMCID: PMC6989705.

2: Long T, Hou J, Yang N, Zhou M, Li Y, Li J, Tang Y, Chen D, Hu S. Utility of
18F-AlF-NOTA-Octreotide PET/CT in the Localization of Tumor-Induced
Osteomalacia. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4202-e4209. doi:
10.1210/clinem/dgab258. PMID: 33864458.

3: Haeger A, Soza-Ried C, Kramer V, Hurtado de Mendoza A, Eppard E, Emmanuel N,
Wettlin J, Amaral H, Fernández R. Al[18F]F-NOTA-Octreotide Is
Comparable to [68Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine
Tumours in the Latin-American Population. Cancers (Basel). 2023 Jan
10;15(2):439. doi: 10.3390/cancers15020439. PMID: 36672388; PMCID: PMC9856643.

4: Ahenkorah S, Cawthorne C, Murce E, Deroose CM, Cardinaels T, Seimbille Y,
Bormans G, Ooms M, Cleeren F. Direct comparison of [18F]AlF-NOTA-JR11
and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine
tumors: Antagonist versus agonist. Nucl Med Biol. 2023 Mar-Apr;118-119:108338.
doi: 10.1016/j.nucmedbio.2023.108338. Epub 2023 Mar 29. PMID: 37018875.

5: Laverman P, D'Souza CA, Eek A, McBride WJ, Sharkey RM, Oyen WJ, Goldenberg
DM, Boerman OC. Optimized labeling of NOTA-conjugated octreotide with F-18.
Tumour Biol. 2012 Apr;33(2):427-34. doi: 10.1007/s13277-011-0250-x. Epub 2011
Oct 19. PMID: 22009690; PMCID: PMC3296034.

6: Hou J, Long T, Yang N, Chen D, Zeng S, Zheng K, Liao G, Hu S. Biodistribution
of 18F-AlF-NOTA-octreotide in Different Organs and Characterization
of Uptake in Neuroendocrine Neoplasms. Mol Imaging Biol. 2021 Dec;23(6):827-835.
doi: 10.1007/s11307-021-01628-7. Epub 2021 Jul 6. PMID: 34231107.

7: Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, Van Cutsem
E, Verslype C, Van Laere K, Bormans G, Deroose CM. [18F]AlF-NOTA-
octreotide PET imaging: biodistribution, dosimetry and first comparison with
[68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med
Mol Imaging. 2020 Dec;47(13):3033-3046. doi: 10.1007/s00259-020-04918-4. Epub
2020 Jul 2. PMID: 32617641.

8: Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L,
Dekervel J, Vandamme T, Lybaert W, den Broeck BV, Laenen A, Clement PM, Geboes
K, Cutsem EV, Stroobants S, Verslype C, Bormans G, Deroose CM.
18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/NOC PET
in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study.
J Nucl Med. 2023 Apr;64(4):632-638. doi: 10.2967/jnumed.122.264563. Epub 2022
Oct 20. PMID: 36265911.

9: Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, Goldenberg DM,
Boerman OC. A novel facile method of labeling octreotide with (18)F-fluorine. J
Nucl Med. 2010 Mar;51(3):454-61. doi: 10.2967/jnumed.109.066902. Epub 2010 Feb
11. PMID: 20150268; PMCID: PMC2908260.

10: Boeckxstaens L, Pauwels E, Vandecaveye V, Deckers W, Cleeren F, Dekervel J,
Vandamme T, Serdons K, Koole M, Bormans G, Laenen A, Clement PM, Geboes K, Van
Cutsem E, Nackaerts K, Stroobants S, Verslype C, Van Laere K, Deroose CM.
Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to
[68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients. EJNMMI
Res. 2023 Jun 1;13(1):53. doi: 10.1186/s13550-023-01003-3. PMID: 37261615;
PMCID: PMC10235004.